Drug Profile
MK 8351
Alternative Names: MK-8351Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antiasthmatics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Asthma in United Kingdom (Inhalation)
- 16 Aug 2013 Preclinical trials in Asthma in United Kingdom (Inhalation)
- 16 Aug 2013 Merck plans a phase I trial for Asthma in the UK (NCT01926002)